

Hiroshige Yoshioka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1304313/publications.pdf>

Version: 2024-02-01

25
papers

8,310
citations

566801

15
h-index

676716

22
g-index

26
all docs

26
docs citations

26
times ranked

8056
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L). <i>Clinical Lung Cancer</i> , 2022, 23, e257-e263.	1.1	10
2	Real-world data on NGS using the OncoPrint DxTT for detecting genetic alterations in non-small cell lung cancer: WJOG13019L. <i>Cancer Science</i> , 2022, 113, 221-228.	1.7	31
3	Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIa Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT). <i>Journal of Clinical Oncology</i> , 2022, 40, 231-241.	0.8	61
4	Crizotinib for recurring non-small cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial. <i>Thoracic Cancer</i> , 2021, 12, 643-649.	0.8	5
5	Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2020, 139, 195-199.	0.9	100
6	A randomized phase 3 study of maintenance therapy with Sunitinib plus best supportive care versus best supportive care after induction therapy with carboplatin plus Sunitinib for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L). <i>Cancer</i> , 2020, 126, 3648-3656.	2.0	2
7	A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302. <i>Oncology</i> , 2019, 97, 327-333.	0.9	5
8	A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402). <i>Lung Cancer</i> , 2019, 135, 175-180.	0.9	24
9	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , 2019, 393, 1819-1830.	6.3	2,347
10	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan. <i>Lung Cancer</i> , 2019, 129, 55-62.	0.9	29
11	Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. <i>International Journal of Clinical Oncology</i> , 2018, 23, 634-640.	1.0	103
12	Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 10, 267-269.	0.4	15
13	Phase II Study of Weekly Amrubicin for Refractory or Relapsed Small Cell Lung Cancer. <i>In Vivo</i> , 2018, 32, 1581-1586.	0.6	2
14	Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer. <i>BMC Cancer</i> , 2018, 18, 6.	1.1	7
15	Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 32298-32304.	0.8	53
16	Consideration of the concordance rate of 22C3 and 28-8 antibody in NSCLC and its relation to the effect of nivolumab. <i>Journal of Clinical Oncology</i> , 2018, 36, 143-143.	0.8	0
17	Trial in progress: Multicenter observational study to evaluate the relationship between gut bacterial flora and their therapeutic or adverse effects in advanced non-small cell lung cancer patients treated with nivolumab. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS9114-TPS9114.	0.8	0
18	Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. <i>Lancet</i> , 2017, 390, 29-39.	6.3	753

#	ARTICLE	IF	CITATIONS
19	A statistical issue regarding the original paper by M. Tamiya and others (Med Oncol (2016) 33:2 DOI) Tj ETQq1 1 0.784314 rgBT /Ove	1.2	9
20	Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study. Lung Cancer, 2016, 101, 1-8.	0.9	118
21	Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating <i>EGFR</i> mutations: Subgroup analysis of <i>LUX-Lung 3</i> . Cancer Science, 2015, 106, 1202-1211.	1.7	99
22	Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR).. Journal of Clinical Oncology, 2014, 32, 8117-8117.	0.8	36
23	CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 2 study. Lancet Oncology, The, 2013, 14, 590-598.	5.1	555
24	Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non-Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study. Journal of Clinical Oncology, 2010, 28, 5240-5246.	0.8	161
25	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncology, The, 2010, 11, 121-128.	5.1	3,794